When is an iliofemoral bypass indicated and what is the recommended perioperative management?

Iliofemoral Bypass: Indications and Perioperative Management

Primary Indications

Iliofemoral bypass is indicated for unilateral iliac artery occlusive disease when the ipsilateral common iliac artery is unsuitable for bypass (occluded from its origin or heavily calcified) but acceptable aortic inflow exists, particularly in patients who are not candidates for aortobifemoral bypass. 1, 2

Specific Clinical Scenarios for Iliofemoral Bypass:

For Claudication:

• Lifestyle-limiting or vocational disability unresponsive to exercise therapy and pharmacotherapy (cilostazol trial)
• Patient must have reasonable likelihood of symptomatic improvement
• Endovascular options exhausted or unfavorable anatomy 2

For Critical Limb Ischemia (CLI):

• Rest pain, non-healing ulcers, or gangrene
• When limb salvage is the goal and patient can tolerate surgery
• Inflow disease must be corrected before addressing outflow disease 1

Anatomic Requirements:

• Unilateral iliac disease with contralateral iliac artery free of significant disease
• Acceptable aortic inflow present
• Suitable recipient femoral artery 1, 2

Alternative Procedures by Clinical Context

Bilateral disease or suitable aortobifemoral candidate: Aortobifemoral bypass remains gold standard (87.5% 5-year patency, 3.3% mortality) 1

High-risk patients with extensive aortoiliac disease: Axillofemoral-femoral bypass (lower patency: 50-76% at 5 years, but acceptable for limited life expectancy) 1

Contralateral iliac suitable for inflow: Femorofemoral bypass alternative, though requires bilateral groin exposure with higher infection risk 1

Preoperative Evaluation (Class I Recommendation)

A comprehensive cardiovascular risk evaluation is mandatory before major vascular surgery. 2 This includes:

• Cardiac assessment: History of MI, heart failure, coronary disease (operative mortality 0.8-5.2% from MI, particularly in CLI patients) 1
• Renal function: Baseline creatinine (renal failure risk 0-4.6%) 1
• Contralateral limb assessment: Bilateral multiplane angiography or CTA to confirm no significant contralateral disease 3
• Donor vessel evaluation: Duplex ultrasound and imaging to confirm adequate inflow 1
• Ankle-brachial index: Baseline measurement (typically <0.4 in CLI, 0.4-0.9 in claudication) 4

Risk Stratification:

• Acceptable surgical candidates: Proceed with iliofemoral bypass
• Poor surgical risk with unilateral disease: Consider crossover iliofemoral bypass (avoids bilateral groin exposure) 3
• Prohibitive surgical risk: Endovascular-first approach if anatomically feasible 2

Perioperative Management

Surgical Technique Considerations:

Graft Material:

• Polyester filament or PTFE for iliofemoral bypass 1
• If concurrent distal bypass needed: autogenous vein mandatory for below-knee popliteal or tibial targets (Class I) 2

Approach:

• Lower abdominal retroperitoneal incision for iliofemoral bypass 4
• Single groin exposure (avoids bilateral groin complications seen with femorofemoral bypass) 3, 5

Concurrent Procedures:

When combined inflow and outflow disease exists, address in this order:

1. Iliofemoral bypass first (establish inflow)
2. Common femoral endarterectomy if needed
3. Profundoplasty if deep femoral disease present
4. Distal bypass only if inadequate collateral flow after inflow correction 1

Immediate Postoperative Monitoring:

Critical parameters to track:

• Femoral pulses (should be palpable immediately)
• Ankle-brachial index (expect improvement to >0.6 in CLI, >0.8 in claudication) 4
• Doppler signals in distal vessels
• Signs of compartment syndrome or reperfusion injury 6

Common complications (12.5% rate):

• Atrial fibrillation (manage medically)
• Acute renal failure (0-4.6% risk, monitor creatinine)
• Early graft thrombosis (requires immediate intervention)
• Wound infection (2-5% rate, lower than bilateral groin procedures) 4, 7

Expected Outcomes

Patency rates for iliofemoral bypass:

• 1-year primary patency: 94-97.5%
• 5-year primary patency: 74.9-92%
• 5-year secondary patency: 79.2-95% 4, 3, 7, 5, 8

These results are superior to femorofemoral bypass (56.9% 5-year primary patency) but inferior to aortobifemoral bypass (87.5% 5-year patency). 1, 5

Limb salvage in CLI:

• 1-year: 85-100%
• 5-year: 79-87% 4, 7

Operative mortality: 3.7-6.2% (lower than major amputation at 4-30%) 1, 4, 7, 5

Factors Predicting Success:

• Best outcomes: Claudication indication (88% symptom resolution) 4, 8
• Worse outcomes: CLI, prior groin surgery, acute thrombosis, need for distal endarterectomy 7, 5
• Age <50 years: More aggressive disease, less durable results (Class IIb evidence) 2

Long-term Surveillance (Class I Recommendations)

For at least 2 years postoperatively, perform periodic evaluations: 2

• Clinical assessment: return/progression of claudication symptoms
• Physical examination: femoral pulse examination
• Ankle-brachial indices at rest and after exercise
• Duplex imaging of entire graft length with peak systolic velocities
• Calculate velocity ratios across any lesions (>2.0 suggests stenosis)

Intervention thresholds:

• Velocity ratio >2.5 or >50% stenosis on imaging
• Declining ABI (>0.15 decrease)
• Recurrent symptoms 2

Key Pitfalls to Avoid

• Do not perform iliofemoral bypass prophylactically in asymptomatic PAD (Class III) 2
• Do not proceed without confirming contralateral iliac artery is disease-free (risk of inadequate inflow) 3
• Do not use synthetic grafts for tibial targets in claudication (Class III) 2
• Do not ignore concurrent outflow disease but correct inflow first 1
• Avoid in patients <50 years with claudication alone unless lifestyle-limiting and no alternatives (less durable results) 2